Integra LifeSciences Cash Flow Statement
NASDAQ: IARTHealth CareMedical/Dental InstrumentsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Integra LifeSciences free cash flow
In fiscal 2025, Integra LifeSciences generated $50.4 million of operating cash flow and spent $81.4 million on capital expenditures. That left free cash flow of -$31.1 million, a free-cash-flow margin of -1.9% of revenue. Free cash flow was down 224.4% from the prior year's $25.0 million.
Integra LifeSciences returned $221,000 to shareholders through share repurchases.
Summary generated from market data by MetaCap's automated system. Methodology
Integra LifeSciences cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -516.47M | -6.94M | 67.74M | 180.55M | 169.07M | 133.89M | 50.20M | 60.80M | 64.74M | 74.56M |
| Net Income growth (YoY) | — | -110.25% | -62.48% | +6.79% | +26.28% | +166.71% | -17.43% | -6.09% | -13.17% | — |
| Depreciation & Amortization | 44.80M | 42.40M | 40.90M | 40.10M | 39.40M | 42.10M | 109.46M | 110.73M | 88.94M | 72.67M |
| Stock-Based Compensation | 18.58M | 24.38M | 20.14M | 27.73M | 36.21M | 19.59M | 21.25M | 20.78M | 21.55M | 17.31M |
| Change in Working Capital | -13.78M | -22.73M | -83.82M | -43.59M | 53.42M | -40.06M | -25.52M | -2.58M | 8.68M | -26.73M |
| Operating Cash Flow | 50.38M | 129.38M | 139.96M | 264.47M | 312.43M | 203.83M | 231.43M | 199.68M | 114.54M | 116.41M |
| Capital Expenditures | -81.44M | -104.42M | -66.86M | -42.34M | -48.02M | -38.89M | -69.54M | -77.74M | -43.50M | -47.33M |
| Investing Cash Flow | -108.06M | -390.81M | -94.18M | -58.58M | -161.44M | -68.07M | -162.67M | -49.70M | -1.22B | -42.62M |
| Share Repurchases | -221.00K | -52.47M | -275.00M | -125.00M | 0 | -100.00M | 0 | 0 | — | — |
| Financing Cash Flow | 28.34M | 237.86M | -229.93M | -251.95M | -98.23M | 121.63M | -8.77M | -180.87M | 1.17B | -15.12M |
| Net Change in Cash | -11.33M | -30.03M | -180.26M | -56.79M | 43.28M | 271.25M | 60.07M | -36.10M | 72.88M | 53.92M |
| Free Cash Flow | -31.05M | 24.96M | 73.09M | 222.13M | 264.40M | 164.94M | 161.90M | 121.94M | 71.04M | 69.08M |
This table shows 10 annual periods of Integra LifeSciences's cash flow statement, from FY 2025 back to FY 2016, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow IART's reporting calendar. What is a cash flow statement?